This year’s prestigious Lasker medical awards recognize a trio of scientists without whom Ozempic and other blockbuster ...

The current state of weight-loss treatments is about to shift with the forthcoming availability of GLP-1 drugs in the ...

to examine potential applications of glucagon-like peptide-1 receptor (GLP-1R) agonists in central nervous system disorders, such as dementia, Parkinson’s disease, substance and alcohol use disorders, ...

The demand for weight loss medications are on the rise, and now, “natural” GLP-1s are being marketed to help you lose weight.

Among patients receiving persistent medication at one year, 61% of patients prescribed semaglutide for obesity achieved at ...

French researchers have developed a new drug delivery system that could cut the dosing schedule for the type 2 diabetes and ...

Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster ...

French researchers have developed a new drug delivery system that could cut the dosing schedule for type 2 diabetes and ...

This ElectroSlim review reveals what sets it apart from other weight loss supplements and explains how it functions in the ...

or recombinant human low dose interleukin-2 (LD IL-2), and Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs). Dr. Arun Swaminathan, Coya’s Chief Business Officer, stated, “There has been ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...